Kimura, Yasuyuki http://orcid.org/0000-0002-7927-9483
Takahata, Keisuke
Shimazaki, Toshiharu
Kitamura, Soichiro
Seki, Chie
Ikoma, Yoko
Ichise, Masanori
Kawamura, Kazunori
Yamada, Makiko
Zhang, Ming-Rong
Higuchi, Makoto
Nishino, Izumi
Suhara, Tetsuya
Article History
Received: 25 May 2021
Accepted: 21 September 2021
First Online: 15 October 2021
Declarations
:
: This study was approved by SOUSEIKAI Hakata Clinic Institutional Review Board and the Radiation Drug Safety Committee and the Institutional Review Board of the National Institute of Radiological Sciences, Japan, and was conducted in compliance with the ethical principles set forth in the Declaration of Helsinki, the standards stipulated in Article 14, Paragraph 3, and Article 80–2 of the Act on Securing Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, Regenerative and Cellular Therapy Products, Gene Therapy Products, and Cosmetics, and Good Clinical Practice (MHW Ordinance No. 28 dated March 27, 1997).
: All subjects gave written informed consent prior to their inclusion in the study.
: Written informed consent was obtained from all participants regarding publishing their data.
: Taisho Pharmaceutical Co., Ltd., MH, and TSu hold a patent for [<sup>11</sup>C]TASP457 and related chemicals as histamine H<sub>3</sub> ligands (Japan patent JP2014047209A). TSh and IN are employees of Taisho Pharmaceutical Co., Ltd.